The content on this site is intended for healthcare professionals only
Clinical data on breast cancer trials
CDK 4/6 inhibitors: Management of side effects
Survivorship care planning for post-menopausal breast cancer patients in Ireland
CDK clinical trial results, benefit, side effects and costs
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Editor's ESMO 2016 roundup
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
CDK4/6 inhibitors for metastatic breast cancer
Who should receive combination therapy for ER positive breast cancer?
ESMO 2016 conference highlights
Lurbinectedin in PARP resistant breast cancer
